Raymond J Dattwyler

List of Publications by Year
in descending order

81 papers	5,906 citations	159358 30 h-index	71532 76 g-index
82 all docs	82 docs citations	82 times ranked	2509 citing authors

#	Article	IF	Citations
1	The Clinical Assessment, Treatment, and Prevention of Lyme Disease, Human Granulocytic Anaplasmosis, and Babesiosis: Clinical Practice Guidelines by the Infectious Diseases Society of America. Clinical Infectious Diseases, 2006, 43, 1089-1134.	2.9	1,795
2	Seronegative Lyme Disease. New England Journal of Medicine, 1988, 319, 1441-1446.	13.9	421
3	Practice Guidelines for the Treatment of Lyme Disease. Clinical Infectious Diseases, 2000, 31, S1-S14.	2.9	308
4	TREATMENT OF LATE LYME BORRELIOSISâ€"RANDOMISED COMPARISON OF CEFTRIAXONE AND PENICILLIN. Lancet, The, 1988, 331, 1191-1194.	6.3	297
5	Four Clones of Borrelia burgdorferi Sensu Stricto Cause Invasive Infection in Humans. Infection and Immunity, 1999, 67, 3518-3524.	1.0	260
6	LYME NEUROBORRELIOSIS: PERIPHERAL NERVOUS SYSTEM MANIFESTATIONS. Brain, 1990, 113, 1207-1221.	3.7	188
7	Amoxycillin plus probenecid versus doxycycline for treatment of erythema migrans borreliosis. Lancet, The, 1990, 336, 1404-1406.	6.3	169
8	Ceftriaxone Compared with Doxycycline for the Treatment of Acute Disseminated Lyme Disease. New England Journal of Medicine, 1997, 337, 289-295.	13.9	169
9	Ceftriaxone as Effective Therapy in Refractory Lyme Disease. Journal of Infectious Diseases, 1987, 155, 1322-1325.	1.9	145
10	Treatment Trials for Post-Lyme Disease Symptoms Revisited. American Journal of Medicine, 2013, 126, 665-669.	0.6	106
11	Nervous System Abnormalities in Lyme Disease. Annals of the New York Academy of Sciences, 1988, 539, 24-34.	1.8	102
12	Antiscience and ethical concerns associated with advocacy of Lyme disease. Lancet Infectious Diseases, The, 2011, 11, 713-719.	4.6	102
13	Mycobacterium marinum infections of the hand. Journal of Hand Surgery, 1987, 12, 428-435.	0.7	101
14	Failure of tetracycline therapy in early lyme disease. Arthritis and Rheumatism, 1987, 30, 448-450.	6.7	83
15	Advances in Serodiagnostic Testing for Lyme Disease Are at Hand. Clinical Infectious Diseases, 2018, 66, 1133-1139.	2.9	82
16	Immunologic Reactivity Against Borrelia burgdorferi in Patients With Motor Neuron Disease. Archives of Neurology, 1990, 47, 586-594.	4.9	79
17	A comparison of two treatment regimens of ceftriaxone in late Lyme disease. Wiener Klinische Wochenschrift, 2005, 117, 393-397.	1.0	79
18	Oral vaccine that breaks the transmission cycle of the Lyme disease spirochete can be delivered via bait. Vaccine, 2006, 24, 4440-4449.	1.7	75

#	Article	IF	Citations
19	Binding of Î±-foetoprotein to murine T cells. Nature, 1975, 256, 656-657.	13.7	74
20	New Chemotherapeutic Approaches in the Treatment of Lyme Borreliosis. Annals of the New York Academy of Sciences, 1988, 539, 352-361.	1.8	74
21	Specific Immune Response in Lyme Borreliosis.. Annals of the New York Academy of Sciences, 1988, 539, 93-102.	1.8	71
22	Point-of-Care Serodiagnostic Test for Early-Stage Lyme Disease Using a Multiplexed Paper-Based Immunoassay and Machine Learning. ACS Nano, 2020, 14, 229-240.	7.3	66
23	Oral Immunization with RecombinantLactobacillus plantarumInduces a Protective Immune Response in Mice with Lyme Disease. Vaccine Journal, 2008, 15, 1429-1435.	3.2	65
24	Direct Diagnostic Tests for Lyme Disease. Clinical Infectious Diseases, 2019, 68, 1052-1057.	2.9	60
25	Protective Immunity and New Vaccines for Lyme Disease. Clinical Infectious Diseases, 2020, 70, 1768-1773.	2.9	50
26	Infection With Multiple Strains of Borrelia burgdorferi Sensu Stricto in Patients With Lyme Disease. Archives of Dermatology, 1999, 135, 1329-33.	1.7	46
27	Outer Surface Protein C Peptide Derived from Borrelia burgdorferi Sensu Stricto as a Target for Serodiagnosis of Early Lyme Disease. Vaccine Journal, 2013, 20, 474-481.	3.2	43
28	Development of a Multiantigen Panel for Improved Detection of Borrelia burgdorferi Infection in Early Lyme Disease. Journal of Clinical Microbiology, 2015, 53, 3834-3841.	1.8	38
29	Ventricular tachycardia associated with Lyme carditis. American Heart Journal, 1991, 121, 1558-1560.	1.2	34
30	Immunologic Aspects of Lyme Borreliosis. Clinical Infectious Diseases, 1989, 11, S1494-S1498.	2.9	32
31	Recombinant Chimeric Borrelia Proteins for Diagnosis of Lyme Disease. Journal of Clinical Microbiology, 2000, 38, 2530-2535.	1.8	32
32	Inhibition of sensitization of T-cells by alpha-fetoprotein. International Journal of Cancer, 1975, 16, 942-945.	2.3	30
33	Response to meta-analysis of Lyme borreliosis symptoms. International Journal of Epidemiology, 2005, 34, 1437-1439.	0.9	30
34	A Perspective on the Treatment of Lyme Borreliosis. Clinical Infectious Diseases, 1989, 11, S1518-S1525.	2.9	29
35	A First-Tier Rapid Assay for the Serodiagnosis of Borrelia burgdorferi Infection. Archives of Internal Medicine, 2001, 161, 2015.	4.3	28
36	Identification of OppA2 Linear Epitopes as Serodiagnostic Markers for Lyme Disease. Vaccine Journal, 2014, 21, 704-711.	3.2	26

#	Article	IF	Citations
37	Carpal tunnel syndrome in Lyme borreliosis. Muscle and Nerve, 1989, 12, 397-400.	1.0	25
38	Cross-reactive antigenic domains of the flagellin protein of Borrelia burgdorferi. Research in Microbiology, 1993, 144, 251-257.	1.0	25
39	Detection of IFN-Î³ Secretion by T Cells Collected Before and After Successful Treatment of Early Lyme Disease. Clinical Infectious Diseases, 2016, 62, 1235-1241.	2.9	25
40	A critical appraisal of the mild axonal peripheral neuropathy of late neurologic Lyme disease. Diagnostic Microbiology and Infectious Disease, 2017, 87, 163-167.	0.8	24
41	LcrV Capture Enzyme-Linked Immunosorbent Assay for Detection of Yersinia pestis from Human Samples. Vaccine Journal, 2005, 12, 339-346.	3.2	23
42	Elimination of Babesia microti Is Dependent on Intraerythrocytic Killing and CD4+ T Cells. Journal of Immunology, 2017, 199, 633-642.	0.4	23
43	Epitope Length, Genospecies Dependency, and Serum Panel Effect in the IR6 Enzyme-Linked Immunosorbent Assay for Detection of Antibodies to Borrelia burgdorferi. Vaccine Journal, 2007, 14, 875-879.	3.2	22
44	Editorial Commentary: Comparison of Lyme Disease Serologic Assays and Lyme Specialty Laboratories. Clinical Infectious Diseases, 2014, 59, 1711-1713.	2.9	21
45	Modulation of Natural Killer Cell Activity by Borrelia burgdorferi. Annals of the New York Academy of Sciences, 1988, 539, 103-111.	1.8	20
46	Recombinant Assay for Serodiagnosis of Lyme Disease Regardless of OspA Vaccination Status. Journal of Clinical Microbiology, 2002, 40, 193-197.	1.8	20
47	Pneumomediastinum as a complication of asthma in teenage and young adult patients. Journal of Allergy and Clinical Immunology, 1979, 63, 412-416.	1.5	18
48	Intranasal delivery of a protein subunit vaccine using a Tobacco Mosaic Virus platform protects against pneumonic plague. Vaccine, 2016, 34, 5768-5776.	1.7	18
49	The year that shaped the outcome of the OspA vaccine for human Lyme disease. Npj Vaccines, 2022, 7, 10.	2.9	18
50	Lymphocyte subsets in women on low dose oral contraceptives. Contraception, 1985, 32, 377-382.	0.8	16
51	Platform technology to deliver prophylactic molecules orally: An example using the Class A select agent Yersinia pestis. Vaccine, 2010, 28, 6714-6722.	1.7	16
52	Scientific evidence and best patient care practices should guide the ethics of Lyme disease activism. Journal of Medical Ethics, 2011, 37, 68-73.	1.0	16
53	Spirochetal Infection of the Central Nervous System. Infectious Disease Clinics of North America, 1990, 4, 731-746.	1.9	16
54	Immunodiagnosis of Lyme Borreliosis. Rheumatic Disease Clinics of North America, 1989, 15, 727-734.	0.8	16

#	Article	IF	Citations
55	Single-dose prophylaxis against Lyme disease. Lancet Infectious Diseases, The, 2007, 7, 371-373.	4.6	15
56	Decorin Binding Proteins A and B in the Serodiagnosis of Lyme Disease in North America. Vaccine Journal, 2014, 21, 1426-1436.	3.2	15
57	Cross-Reactive Epitopes in Borrelia burgdorferi p66. Vaccine Journal, 2015, 22, 840-843.	3.2	14
58	LYME DISEASE IN EUROPE AND NORTH AMERICA. Lancet, The, 1987, 329, 681.	6.3	12
59	Antigen-Specific T-Cell Anergy in Progressive Mycobacterium marinum Infection in Humans. Annals of Internal Medicine, 1987, 107, 675.	2.0	10
60	Lyme Borreliosis: An Overview of the Clinica Manifestations. Laboratory Medicine, 1990, 21, 290-292.	0.8	10
61	Specificity of Human B-Cell Responses of Immunodominant Antigens of Borrelia burgdorferi. Annals of the New York Academy of Sciences, 1988, 539, 398-399.	1.8	9
62	Reply to Pollock, Donta, Wilson, and Arne. Clinical Infectious Diseases, 2007, 44, 1137-1139.	2.9	9
63	Linear B Cell Epitopes Derived from the Multifunctional Surface Lipoprotein BBK32 as Targets for the Serodiagnosis of Lyme Disease. MSphere, 2019, 4, .	1.3	9
64	Antiâ€“Tumor Necrosis Factorâ€“Î± Activation ofBorrelia burgdorferiSpirochetes in Antibioticâ€Treated Murine Lyme Borreliosis: An Unproven Conclusion. Journal of Infectious Diseases, 2007, 196, 1865-1866.	1.9	7
65	A Commentary on the Treatment of Early Lyme Disease. Clinical Infectious Diseases, 2010, 50, 521-522.	2.9	7
66	Borrelia burgdorferi -specific IgA in Lyme Disease. EBioMedicine, 2017, 19, 91-97.	2.7	7
67	Treatment of Lyme Borreliosis. Rheumatic Disease Clinics of North America, 1989, 15, 747-755.	0.8	7
68	The Immunology of Lyme Borreliosis. Laboratory Medicine, 1990, 21, 305-309.	0.8	6
69	Detection of IFN-Î³ Secretion in Blood Samples Collected Before and After Treatment of Varying Stages of Lyme Disease. Clinical Infectious Diseases, 2021, 73, 1484-1491.	2.9	6
70	Controlled prospective study of factor IX concentrate therapy and immunodeficiency. American Journal of Hematology, 1989, 31, 71-72.	2.0	3
71	Antibiotic treatment of Lyme borreliosis. Biomedicine and Pharmacotherapy, 1989, 43, 421-426.	2.5	2
72	IFNÎ³ production in peripheral blood of early Lyme disease patients to hLFAÎ±L (aa326-345). BMC Musculoskeletal Disorders, 2002, 3, 25.	0.8	2

#	Article	IF	Citations
73	Chemoprophylaxis against Lyme disease. Lancet Infectious Diseases, The, 2008, 8, 146-147.	4.6	2
74	Lyme borreliosis. International Journal of Antimicrobial Agents, 1994, 3, 251-258.	1.1	1
75	Lyme disease antiscience â€“ Authors' reply. Lancet Infectious Diseases, The, 2012, 12, 362-363.	4.6	1
76	1760. Interferon Gamma Release Assay for Diagnosis of Lyme disease. Open Forum Infectious Diseases, 2018, 5, S61-S61.	0.4	1
77	Inverted T helper/T suppressor lymphocyte ratio is not a reliable indicator of coexistent HIV infection in the presence of carcinoma: Report of a patient with ovarian carcinoma and inverted THTS ratio. Gynecologic Oncology, 1989, 34, 119-121.	0.6	0
78	Borrelia burgdorferi in the Central Nervous System-Reply. JAMA - Journal of the American Medical Association, 1992, 268, 873.	3.8	0
79	The 10 Most Common Questions About Lyme Disease. Infectious Diseases in Clinical Practice, 1995, 4, 104-106.	0.1	0
80	The Reply. American Journal of Medicine, 2014, 127, e11-e12.	0.6	0
81	Response letter to Drs. Halperin and Greenberg. Diagnostic Microbiology and Infectious Disease, 2017, 88, 108-109.	0.8	0